Loading...

Optimind Pharma Corp.

OMND.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.01
CA$0.005(100.00%)

Optimind Pharma Corp. (OMND.CN) Stock Overview

Explore Optimind Pharma Corp.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap1.1M
P/E Ratio-1.23
EPS (TTM)$-0.01
ROE8.09%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.00

OMND.CN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Optimind Pharma Corp. (OMND.CN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 51.85, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.23 and a market capitalization of 1.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

51.85RSI (14)
0.00MACD
33.33ADX
Stats data is not available for OMND.CNStats details for OMND.CN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for OMND.CNAnalyst Recommendations details for OMND.CN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Optimind Pharma Corp. operates as a pharmaceutical company in Canada. The company offers psychedelic therapies for treatment of post-traumatic stress syndrome, anxiety, depression, and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities. It also operates a clinic that provides medical cannabis and other alternative treatments for various medical ailments, including ketamine-enhanced psychotherapy. The company is headquartered in Toronto, Canada.

CEO

David Goodman

Headquarters

TD Centre, North Tower, Toronto, ON

Founded

2022

Frequently Asked Questions

;